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Objectives: Several preference-based health-related quality of life (HRQoL) instruments have been published and
widely used in different populations. However no consensus has emerged regarding the most appropriate instrument
in therapeutic area of stable angina. This study compared and validated the psychometric properties of two generic
preference-based instruments, the EQ-5D and SF-6D, among Chinese stable angina patients.
Methods: Convergent validity of the EQ-5D and SF-6D was examined with eight a priori hypotheses from stable
angina patients in conjunction with Seattle Angina Questionnaire (SAQ). Responsiveness was compared using the
effect size (ES), relative efficiency (RE) and receiver operating characteristic (ROC) curves. Agreement between the
EQ-5D and SF-6D was tested using intra-class correlation coefficient (ICC) and Bland-Altman plot. Factors affecting
utility difference were explored with multiple linear regression analysis.
Results: In 411 patients (mean age 68.08 ± 11.35), mean utility scores (SD) were 0.78 (0.15) for the EQ-5D and 0.68
(0.12) for the SF-6D. Validity was demonstrated by the moderate to strong correlation coefficients (Range: 0.368-0.594,
P< 0.001) for five of the eight hypotheses in both the EQ-5D and SF-6D. There were no serious floor effects
for the EQ-5D and SF-6D, but ceiling effects for the EQ-5D were large. The areas under ROC of them all exceeded 0.5
(0.660-0.814, P< 0.001). The SF-6D showed a better discriminative capacity (ES: 0.573 to 1.179) between groups with
different stable-angina-specific health status than the EQ-5D (ES: 0.426 to 1.126). RE suggested that the SF-6D
(RE: 44.8 to 177.8%) was more efficient than the EQ-5D except for physical function. Poor agreement between them
was observed with ICC (0.448, P< 0.001) and Bland-Altman plot analysis. Multiple liner regression showed that clinical
variables significantly (P< 0.05) influenced differences in utility scores between the EQ-5D and SF-6D.
Conclusions: Both EQ-5D and SF-6D are valid and sensitive preference-based HRQoL instruments in Chinese stable
angina patients. The SF-6D may be a more effective tool with lower ceiling effect and greater sensitivity. Further study
is needed to compare other properties, such as reliability and longitudinal response.
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There is an increasing demand for cost-utility analysis
(CUA), which allows decision-makers to compare the
value of interventions for different health problems and
has been adopted by many countries such as the UK and
US [1,2]. The most commonly used outcome indicator
in CUA is the quality adjusted life year (QALY) which* Correspondence: jingwu@tju.edu.cn
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and a utility value representing quality of life for that
particular health state [3]. Utility values usually range
from 1 (full health) to 0 (death) and direct methods
of measuring utilities (e.g. standard gamble or time
trade-off ) are complex and time-consuming. As an
alternative, preference-based instruments are increasingly
used in clinical studies and population surveys to generate
utility scores [4]. They allow each health status to be
described using a simple health status classification
system, which can then be used to calculate utility scores. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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instruments including the Quality of Well Being (QWB)
[6], Health Utilities Index (HUI) [7], EQ-5D [8], Assessment
of Quality of Life (AQoL) [9] and the SF-6D [10] have been
published and widely used in different populations.
Given its low respondent burden, the EQ-5D has
gained widespread use in clinical studies and population
surveys. The EQ-5D has a number of country-specific
choice-based preference weights, including weights for
the UK, the US, Canada [11], Japan [7] and China [12].
In the UK, National Institute for Health and Clinical
Excellence (NICE) currently suggests that the most
preferred preference-based instrument is the EQ-5D but
recognizes that the EQ-5D may not be appropriate in all
circumstances [1]. The SF-6D, which is derived from the
36-item Short Form Health Survey (SF-36), is one of
the most widely used generic measures of HRQoL in
clinical trials. The major reason for developing SF-6D
is to considerably extending the scope for undertaking
economic evaluation in health care using existing and
future SF-36 data sets [10]. Several studies have compared
EQ-5D with SF-6D in different patient groups, including
chronic prostatitis [13], chronic heart failure [14],
coronary heart disease [15], chronic pain [16], type 2
diabetes [17], inflammatory arthritis [18] and mental
health [19]. Fei-Li Zhao et al. found that both EQ-5D
and SF-6D are demonstrated to be valid and sensitive
HRQoL measures in Chinese chronic prostatitis patients,
with SF-6D showing better HRQoL dimension coverage,
greater sensitivity, and lower ceiling effect [13]. While,
Marko Obradovic et al. found that EQ-5D scores were
lower than SF-6D scores in patients with chronic pain,
with EQ-5D showing higher construct validity and
responsiveness [16]. In general, the two measures are not
equivalent and the validity and comparative responsiveness
of the EQ-5D and SF-6D differ depending on the popula-
tion [13-19]. The choice of instrument to measure HRQoL
may have potential implications for decision-making [18].
Evidence comparing the performance of these instruments
is needed to inform the selection of the most appropriate
instrument. In addition, the evidence requires cumulative
results from different settings and types of study [20].
Stable angina, the cardinal symptom of coronary artery
disease (CAD), is a major debilitating health condition with
common chronic symptoms of intermittent, reversible
chest pain or discomfort [21]. In China, approximately 7.7
thousand per million people have CAD and about half of
them suffer from angina [22,23]. Stable angina has a major
negative impact on health-related quality of life (HRQoL),
including poor general health status, pain, impaired role
functioning, activity restriction, inability to self-manage,
and psychological distress [24]. HRQoL measurement
among patients with stable angina is thus important
for evaluation of new health technologies and resourceallocation decisions. Cardiac trials commonly include the
collection of different disease-specific and generic
measures of health status, such as the Seattle Angina
Questionnaire (SAQ) [25], Angina Pectoris Quality of
Life Questionnaire (APQLQ) [26], SF-36 [27], and the
Nottingham Health Profile (NHP) [28]. However, these
instruments can’t be used to elicit utility values for calcu-
lating QALYs, which is a fundamental component in CUA
as mentioned above. As the management of stable angina
patients could potentially involve substantial resource
consumption [29], providing preference-based measures
that can be incorporated into economic evaluation is
particularly important. Establishing practicality and validity
of these measures is required before their application
[30]. To the best of our knowledge, no preference-based
instrument has been validated among stable angina pa-
tients. Therefore, the objective of this study was to evalu-
ate the validity and sensitivity of the EQ-5D and SF-6D on
stable angina patients and further to evaluate and compare
the performance of these two instruments.
Methods
Study design and patient recruitment
A survey was conducted in two cities of China, Tianjin
(northern China) and Chengdu (southern China),
from July to December, 2011. Stable angina patients
were recruited in two tertiary hospitals in Tianjin and two
community health service centers (CHS) in Chengdu as
chronic illness is managed in communities in Chengdu,
but not in Tianjin.
Patients were included in the study if they were
18 years or above and had been clinically diagnosed with
stable angina by their attending physicians based on
clinical symptoms, examinations of coronary angiography,
dual source Computer Tomography (CT), and history of
CAD. Additional criterion included typical angina
symptoms with a report of at least one episode of
chest pain in the previous 3 months. Patients were
excluded from participating if they had experienced
acute myocardial infarction or coronary revascularization
such as coronary artery bypass grafting surgery and percu-
taneous intervention in the previous 6 months. Patients
were also excluded if they had any active exacerbation of
gastrointestinal (GI) problems, such as an ulcer, or if they
were unable to differentiate between their GI symptoms
and angina pain. These criteria were used to help increase
the likelihood that patients’ chest pain was cardiac in
nature rather than non-cardiac.
The study protocol was approved by the Institutional
Review Board (IRB) of Tianjin University, and written
informed consent concerning the conduct of the survey
was obtained from each subject before participating in the
study. Patients were interviewed by a trained interviewer
with a standardized questionnaire. The questionnaire
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comorbid conditions (hypertension, diabetes mellitus, and
hyperlipidemia), and life style questions followed by the
instruments of the SAQ, EQ-5D, EQ-VAS, and SF-6D.
The patient-reported outcomes including EQ-5D and
SF-6D measures were completed by the patients themselves.
The procedure and questionnaire used were identical
between the two cities.
Instruments
The EQ-5D is a brief, multi-attribute, generic, preference-
based HRQoL instrument. Its descriptive system covers five
dimensions including mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. Each dimension
has three response levels (no problem, some problems, and
severe problems). The EQ-5D descriptive system generates
243 health states, each of which was assigned a utility score
ranging from −0.59 to 1.00 (full health). The utility scoring
algorithm adopted in this study was developed using
time trade-off (TTO) based preference scores from a
China general population [12]. The EQ-5D also includes a
20-cm vertical VAS, with 0 and 100 representing worst
and best imaginable health states, respectively. The simpli-
fied Chinese version of the EQ-5D/VAS was verified in
Chinese population [31,32].
The SF-6D is derived from the SF-36 and covers six
dimensions including physical functioning, role limita-
tion, social functioning, pain, mental functioning, and
vitality. Each dimension has four to six response levels.
Totally the SF-6D system defines 18,000 health states with
a utility score ranging from 0.29 to 1.00 [10]. The SF-6D
utility scoring algorithm used in this study was derived
from a representative sample of the UK general popula-
tion using the Standard Gambling (SG) method, since
no Chinese preferences were available [10]. The Chinese
version of the SF-6D was translated by Lam et al. in
Hong Kong, which was proven to be feasible, acceptable,
reliable, and valid in a Chinese population [33].
The SAQ is a disease-specific instrument for patients
with angina with 19-item self-administered questions on
five dimensions including exertional capacity scale (ECS),
anginal stability scale (ASS), anginal frequency scale (AFS),
treatment satisfaction scale (TSS), and the disease percep-
tion scale (DPS) [25]. The SAQ is scored by assigning each
response an ordinal value, beginning with 1 for the
response that implies the lowest level of functioning to 5
that implies the highest level of functioning, and summing
across items for each of the 5 dimensions. Scale scores for
each dimension are then transformed to a 0 to 100 range
by subtracting the lowest possible, dividing by the range of
the scales, and multiplying by 100. As each scale monitors
a unique dimension, no summary score is generated. The
Chinese SAQ has been shown to be a valid, responsive and
reliable instrument [34].Data analyses
Descriptive statistics
Descriptive statistics were performed to characterize the
sample and the scores of the EQ-5D/VAS, SF-6D, and
SAQ. Continuous variables are presented as mean,
standard deviation (SD) and categorical variables are
shown in the number and proportion of the sample
within each group.Construct validation
Convergent validity of the EQ-5D and SF-6D was
assessed by examining their association with the SAQ
and EQ-VAS at the domain and scale level. Based on the
literature and clinical experience, eight a priori hypotheses
were generated where moderate-to-strong correlations
were expected, namely: 1) the EQ-5D and SF-6D utility
scores with SAQ physical limitation; 2) the EQ-5D and
SF-6D utility scores with SAQ angina stability; 3) the
EQ-5D and SF-6D utility scores with SAQ angina fre-
quency; 4) the EQ-5D and SF-6D utility scores with SAQ
treatment satisfaction; 5) the EQ-5D and SF-6D utility
scores with SAQ disease perception; 6) the EQ-5D and
SF-6D utility scores with the EQ-VAS; 7) the EQ-5D pain/
discomfort and SF-6D pain with SAQ angina frequency;
8) the EQ-5D performing usual activities and the SF-6D
physical function with the SAQ physical limitation.
The correlation was estimated with Spearman’s rank
correlation coefficient, with p > 0.5 considered strong
correlation, 0.35 to 0.5 considered moderate correlation,
and 0.2 to 0.34 weak correlation [35].
The ‘known-group’ method was used to examine the
discriminative validity of the EQ-5D and SF-6D
based on its ability to discriminate among patients
with different subgroups [13,36]. Patients were grouped
according to socioeconomic status, duration of CAD,
presence of other medical conditions and the EQ-VAS.
We classified the EQ-VAS scores into four groups,
namely<65 (bad), 65 to 79 (fair), 80 to 89 (good), and
90 to 100 (excellent) [37]. Subjects with poorer health
status were hypothesized to have lower utility scores for
these two instruments. Nonparametric Mann–Whitney U
tests were performed to identify statistically signifi-
cant effects of dichotomous variables on utility scores,
while Kruskal-Wallis H tests for polychromous variables.Discriminative capacity of the EQ-5D and SF-6D
Ceiling and floor effects (proportion of respondents
with the best and worst possible theoretical scores,
respectively) were calculated for the EQ-5D and SF-6D.
Ceiling and floor effects were considered small if ≤15%
of patients occupy the best or worst health states, re-
spectively, and serious if >15% of patients occupy
these states [18].
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instruments to detect clinically relevant differences
among stable angina patients were compared using the
effect size (ES), relative efficiency (RE) statistics, and
receiver operating characteristic (ROC) curves. The ROC
curve procedure provides a useful method of evaluating
the performance of measures against external indicators
of health status. The utility measure that generates the
largest area under the ROC curve is regarded as the most
sensitive at detecting differences in the external indicator.
A measure with perfect discrimination would generate an
area under the curve (AUC) score of 1.0, whilst a measure
with less discriminatory power would generate an
AUC score of less than 0.5 [30]. In this analysis, the
performance of the EQ-5D and SF-6D was evaluated
against the five dimensional scales of the SAQ as an
external indicator of health status. Scores for each scale
were divided into two groups (>= 50 and<50) indicating
better cardiac functioning and worse functioning [38]. ES
was used to define the discriminative capacity, and was
computed as the difference between the mean of the two
groups mentioned above, divided by the pooled standard
deviation. The pooled standard deviation was estimated
from the corrected standard errors and the weighted
number of individuals in the groups [39]. General
guidelines define an effect size of 0.2 as small, 0.5 as
moderate, and 0.8 as large [40]. This classification
was used to interpret differences in the discriminative
capacity of the instruments studied. RE statistic is defined
as the ratio of the square of the t-statistic of the comparator
instrument (assumed to be the SF-6D utility score) over
the square of the t-statistic of the reference instrument
(assumed to be the EQ-5D utility score). The coefficient
higher than 1.0 indicates that the SF-6D is more sensitive
than the EQ-5D at detecting differences in external
indicators of health with the given sample size, whilst
the coefficient lower than 1.0 indicates less sensitivity
to detect differences [41].
Level of agreement between the EQ-5D and SF-6D
The degree of agreement between utility scores of
the EQ-5D and SF-6D was assessed by the intra-class
correlation coefficient (ICC) and the Bland-Altman
plot. The ICC was computed with the random-effects
linear regression model. Coefficients above 0.7 suggest a
strong agreement [42]. The paired comparison between
the EQ-5D and SF-6D utility scores was made with
Wilcoxon’s signed rank test. In the Bland-Altman plot,
the average of the two measurements was plotted on the
x-axis, and the difference between the two measurements
on the y-axis, where the SF-6D was the subtrahend. The
deviation of the difference from 0, which implies total
agreement, indicates the degree of agreement for each
subject on the plot [43].Factors affecting utility difference between the EQ-5D and
SF-6D
The factors involved in the variation of the utility difference
between the EQ-5D and SF-6D were explored with
multiple liner regression (MLR). The utility difference
between the EQ-5D and SF-6D was entered as the
dependent variable and individual characteristics including
age, gender, education, working status, income, BMI,
comorbid conditions, disease duration, SAQ scores,
and the EQ-VAS for global health status were treated
as independent variables.
All data were entered into a database using EpiData
(Epidata version 3.1, Epidata Association, Odense,
Denmark) and analyzed using STATA 10.0 (STATA
Corp LP, Texas, USA).Results
Characteristics of patients
We obtained 411 valid answers from 423 participants
with a response rate of 97.16% (Table 1). Half of the
patients were women (50.36%), the mean age was 68.08
(11.35) years, and almost 25% had less than six years of
schooling. 77.86% of the patients were retired. A high
percentage of respondents reported comorbidities includ-
ing hypertension (56.69%), diabetes (25.30%), and hyper-
lipidemia (21.17%). Except for angina stability, the mean
scores of other SAQ subscales were higher than 50,
indicating better functioning. The mean (SD) scores
were 0.78 (0.15) for the EQ-5D, 0.68 (0.12) for the
SF-6D and 71.23 (12.35) for the EQ-VAS.Construct validation
Convergent validity was demonstrated by the moder-
ate to strong correlation coefficients (range: 0.368-0.594,
P< 0.001) for five of eight a priori hypotheses in both the
EQ-5D and the SF-6D (Table 2). Correlations between the
utility scores from these two instruments with the scores
for SAQ angina stability were weak, while the correlations
between utility and the SAQ physical limitation, SAQ
disease perception, and the EQ-VAS scores were relatively
strong. Meanwhile, the SAQ physical limitation score
correlated strongly with the EQ-5D usual activities and
the SF-6D physical function.
Table 3 presents the univariate analyses for the SF-6D
and EQ-5D utility scores within subgroups. Hypothesis
for known-group discriminative validity was confirmed
by the differences in utility scores among groups with
different health status measured by EQ-VAS. Moreover,
both measures discriminated between female and male.
Another significant difference in the SF-6D was observed
among patients with different education levels, whereas in
the EQ-5D, significant difference was observed for the
presence of acute medical conditions.
Table 1 Sociodemographics and characteristics of Chinese patients with stable angina (N= 411)
Sociodemographic N (%) Clinical N (%)
Age (Mean ± SD) 68.08 ± 11.35 BMI (Mean ± SD) 24.10 ± 3.76
Female 207 (50.36) Presence of acute medical condition 64 (15.57)
Education With hypertension 233 (56.69)
Bachelor and above 41 (9.98) With diabetes mellitus 104 (25.30)
High school 144 (35.04) With hyperlipidemia 87 (21.17)
Middle school 125 (30.41) Years with CAD (Mean ± SD) 6.86 ± 7.13
Primary and below 101 (24.57) Patient sources
Working status Inpatients 140 (34.06)
Working 50 (12.17) Outpatients 92 (22.38)
Retired 320 (77.86) Home 179 (43.55)
Others 41 (9.98) SAQ (Mean ± SD)
Marriage status Physical limitation 61.80 ± 13.58
Single 3 (0.73) Angina stability 40.45 ± 34.64
Married 320 (77.86) Angina frequency 66.40 ± 26.84
Divorced/ Widowed 88 (21.41) Treatment satisfaction 61.56 ± 14.42
Monthly household income Disease perception 58.33 ± 15.89
<=2500 102 (24.82) EQ-VAS score 71.23 ± 12.35
(2500–4500) 183 (44.53) EQ-5D utility score 0.78 ± 0.15
[4500–10000) 109 (26.52) SF -6D utility score 0.68 ± 0.12
>= 10000 17 (4.14)
Tianjin 212 (51.58)
CAD: Coronary artery disease; SAQ: Seattle Angina Questionnaire; EQ-VAS: EuroQol visual analog scale; EQ-5D: EuroQol-5D; SF-6D: Short form-6D.













Utility a 0.496*** 0.243*** 0.313*** 0.281*** 0.410*** 0.455***
Mobility −0.303*** 0.080 0.068 0.036 −0.030 −0.030
Self-care −0.322*** 0.123* 0.119* 0.106* 0.002 −0.001
Usual activities −0.594*** −0.320*** −0.229*** −0.392*** −0.496*** −0.326***
Pain/discomfort −0.131** −0.318*** −0.391*** -0.271*** −0.347*** −0.388***
Anxiety/depressed −0.283*** −0.238*** −0.356*** −0.287*** −0.370*** −0.528***
SF-6D
Utility a 0.553*** 0.313*** 0.365*** 0.404*** 0.511*** 0.470***
Physical function −0.491*** 0.036 −0.147** −0.016 −0.132** −0.248***
Role limitation −0.446*** −0.168*** −0.315*** −0.331*** −0.315*** −0.324***
Social function −0.531*** −0.223*** −0.235*** −0.269*** −0.364*** −0.313***
Pain −0.523*** −0.366*** −0.368*** −0.386*** −0.560*** −0.381***
Mental health −0.227*** −0.297*** −0.370*** −0.366*** −0.395*** −0.494***
Vitality −0.338*** −0.355*** −0.372*** −0.353*** −0.414*** −0.543***
*P< 0.05 (two-tailed); **P< 0.01 (two-tailed); ***P< 0.001 (two-tailed).
aFor these variables, higher scores indicate better health, while for other variables higher scores indicate worse health.
Hypothesized moderate-to-strong correlations were bolded.
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Table 3 Univariate analyses for SF-6D and EQ-5D utility scores within subgroups
N (%) EQ-5D SF-6D
Mean (SD) P Mean (SD) P
Age (Years) 0.062 0.552
<=44 12 (2.92) 0.79 (0.12) 0.65 (0.13)
(45–60) 92 (22.38) 0.79 (0.14) 0.67 (0.12)
(61–74) 170 (41.36) 0.80(0.14) 0.68 (0.12)
>= 75 137 (33.33) 0.76 (0.16) 0.68 (0.11)
Gender 0.001 0.000
Female 207 (50.36) 0.77 (0.13) 0.66 (0.11)
Male 204 (49.64) 0.80 (0.16) 0.70 (0.12)
Education 0.069 0.007
Bachelor and above 41 (9.98) 0.81(0.15) 0.72 (0.10)
High school 144 (35.04) 0.80 (0.13) 0.69 (0.11)
Middle school 125 (30.41) 0.78 (0.16) 0.67 (0.12)
Primary and below 101 (24.57) 0.75 (0.15) 0.65 (0.12)
Monthly Household income 0.127 0.074
<=2500 102 (24.82) 0.76 (0.18) 0.65 (0.13)
(2500–4500) 183 (44.53) 0.79 (0.13) 0.69 (0.11)
[4500–10000) 109 (26.52) 0.79 (0.15) 0.67 (0.11)
>= 10000 17 (4.14) 0.86 (0.10) 0.72 (0.09)
Years with CAD 0.489 0.319
<1 65 (15.82) 0.78 (0.10) 0.67 (0.11)
[1–5) 143 (34.79) 0.80 (0.14) 0.69 (0.12)
[5–10) 74 (18.00) 0.78 (0.17) 0.67 (0.11)
>= 10 129 (31.39) 0.77 (0.16) 0.67 (0.11)
Presence of acute medical condition 0.001 0.106
Yes 64 (15.57) 0.74 (0.11) 0.66 (0.13)
No 347 (84.43) 0.79 (0.15) 0.68 (0.11)
Presence of chronic medical condition 0.066 0.574
Yes 338 (82.24) 0.78 (0.15) 0.68 (0.12)
No 73 (17.76) 0.81 (0.11) 0.67 (0.10)
EQ-VAS 0.000 0.001
<65 102 (24.82) 0.70 (0.15) 0.59 (0.11)
(65, 79) 162 (39.42) 0.78 (0.12) 0.68 (0.11)
(80, 89) 120 (29.20) 0.83 (0.15) 0.72 (0.11)
(90, 100) 27 (6.57) 0.92 (0.10) 0.78 (0.08)
The data in boldface mean P< 0.05.
CAD: Coronary artery disease; EQ-VAS: EuroQol visual analog scale; EQ-5D: EuroQol-5D; SF-6D: Short form-6D.
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There was ceiling effect for the EQ-5D utility score
(15.57%) and no patient scored at the ceiling of the SF-6D.
However, serious ceiling effects existed in all domains of
the EQ-5D, and the largest ceiling effect were observed for
mobility (84.18%) and self-care (86.62%) domains. High
ceiling effects were also observed in the social function
domain (29.20%) and role limitation (26.52%) of theSF-6D. No patient scored at the floor of the EQ-5D utility,
and 0.24% scored at the floor of the SF-6D utility. Floor
effects were negligible on most domains, except for role
limitation (21.17%) and vitality (17.03%) from the SF-6D.
The distribution of responses who reported limitations
on the SF-6D dimensions was 15.57% among individuals
who reported no limitations on all the EQ-5D dimensions.
In this group, a majority of individuals were classified as
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and social function (67.19%). Nevertheless, 96.87% of the
respondents were classified as level 2 or higher in the
physical functioning dimension, 87.50% of the respondents
in the vitality dimension, 82.81% of the respondents in the
mental health dimension, and 65.62% of the respondents
in the pain dimension.
Sensitivity of the EQ-5D and SF-6D
Table 4 presents effect sizes (ES), relative efficiency (RE)
statistics, and area scores under the receiver operatingTable 4 Efficiency of the EQ-5D and SF-6D to detect clinically





>= 50 351 0.81 (0.13) 1.126*
<50 60 0.65 (0.20)
SF-6D Physical limitation
>= 50 351 0.69 (0.11) 0.981*
<50 60 0.59 (0.10)
EQ-5D Angina stability
>= 50 232 0.82 (0.14) 0.587*
<50 179 0.74 (0.14)
SF-6D Angina stability
>= 50 232 0.71 (0.11) 0.706*
<50 179 0.63 (0.11)
EQ-5D Angina frequency
>= 50 313 0.80 (0.16) 0.426*
<50 98 0.74 (0.10)
SF-6D Angina frequency
>= 50 313 0.69 (0.11) 0.573*
<50 98 0.63 (0.11)
EQ-5D Treatment satisfaction
>= 50 323 0.80 (0.15) 0.495*
<50 88 0.73 (0.12)
SF-6D Treatment satisfaction
>= 50 323 0.70 (0.11) 0.778*
<50 88 0.61 (0.10)
EQ-5D Disease perception
>= 50 318 0.81 (0.14) 0.707*
<50 93 0.71 (0.13)
SF-6D Disease perception
>= 50 318 0.71 (0.11) 1.179*
<50 93 0.58 (0.10)
*P< 0.001. For ROC curve, P< 0.001 indicates that AUC statistically significantly grea
aEffect sizes were computed as the difference between the means of the groups di
bReference is EQ-5D measure.
EQ-5D: EuroQol-5D; SF-6D: Short form-6D; SAQ: Seattle Angina Questionnaire; SD: st
AUC: area under ROC curves; CI: confidence interval.characteristic curves (AUC) for the EQ-5D and SF-6D
utility scores between groups based on the dichotomous
health status variables. Differences between the five
groups for the SF-6D utility scores were large, with
ES ranging from 0.573 to 1.179. Most effect sizes on
the EQ-5D were moderate or large (ranging from 0.
426 to 1.126).
Statistically significant differences (P< 0.001) were found
for all between-group comparisons on both the EQ-5D
and SF-6D utility scores. RE statistic calculation showed
that the EQ-5D was found to be 24.2% more efficient atrelevant difference
t Test REb ROC curve
t statistic P AUC 95%CI
8.062 0.000 1.000 0.762* (0.690, 0.834)
7.020 0.000 0.758 0.765* (0.710, 0.820)
5.901 0.000 1.000 0.660* (0.607, 0.712)
7.100 0.000 1.448 0.694* (0.643, 0.744)
3.677 0.000 1.000 0.662* (0.606, 0.717)
4.953 0.000 1.814 0.661* (0.601, 0.722)
4.120 0.000 1.000 0.664* (0.609, 0.719)
6.466 0.000 2.463 0.724* (0.667, 0.781)
5.998 0.000 1.000 0.696* (0.640, 0.751)
9.997 0.000 2.778 0.814* (0.767, 0.860)
ter than 0.5.
vided by the pooled standard deviation.
andard deviation; ROC: receiver operating characteristics; RE: relative efficiency;
Table 5 Multiple linear regression analyses for utility
difference between the EQ-5D and SF-6D
Independent variables Utility difference#
Coefficient (95%CI) P
Age −0.001 (−0.003, 0.001) 0.089
Male −0.010 (−0.033, 0.014) 0.419
Education (vs. Bachelor and above)
High school 0.014 (−0.026, 0.054) 0.491
Middle school 0.034 (−0.007, 0.075) 0.105
Primary and below 0.028 (−0.016, 0.072) 0.211
Working status (vs. working)
Retired 0.006 (−0.033, 0.046) 0.752
Others 0.006 (−0.044, 0.056) 0.807
Marriage status (vs. married)
Single −0.042 (−0.172, 0.088) 0.525
Divorced/ Widowed −0.004 (−0.034, 0.026) 0.770
Monthly Household income (vs. >= 4500)
<4500 −0.018 (−0.042, 0.008) 0.173
BMI −0.001 (−0.004, 0.002) 0.453
Presence of acute medical
condition (vs. none)
0.043 (0.011, 0.075)* 0.008
Hypertension (vs. none) 0.022 (−0.001, 0.045) 0.065
Diabetes mellitus (vs. none) −0.002 (−0.027, 0.024) 0.897
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tions. While when subjects were categorized in terms of
angina stability and angina frequency, the SF-6D was
44.8% and 81.4% more efficient than the EQ-5D.
When subjects were categorized in terms of treatment
satisfaction and disease perception, the SF-6D was
146.3% and 177.8% more efficient than the EQ-5D.
The AUC scores generated by the ROC curves
provided a further indication of the sensitivity of the
two instruments. The AUC scores of both instruments
above 0.5 with statistical significance suggested that the
instruments were able to detect the difference between
patients with better and worse functioning in the five
domains of the SAQ. Except for angina frequency, the
SF-6D generated higher AUC scores than the EQ-5D,
indicating greater discriminatory power.
Level of agreement between the EQ-5D and SF-6D
The degree of agreement between the scores of EQ-5D
and SF-6D was assessed by the Bland-Altman plot and by
computing an intra-class correlation coefficient (ICC).
Poor agreement between the EQ-5D and SF-6D utility
scores was observed with a low ICC of 0.448. Wilcoxon’s
signed rank test showed that the difference was significant
(P< 0.001). Bland-Altman analysis indicated lack of agree-
ment between the two measures with the mean difference
of 0.106 (Figure 1). The analysis indicated that the 95%
limits of agreement between the EQ-5D and SF-6D ranged
from −0.123 to 0.335 and over 95% points lay within
those limits. A systematic variation was observed, with
higher SF-6D at lower mean utility, and lower SF-6D at
higher mean utility scores.
Factors affecting utility difference between the EQ-5D
and SF-6D
Table 5 presents the results of the multiple linear regression
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Figure 1 Bland-Altman plot of difference in utility scores
between EQ-5D and SF-6D.as the dependent variable. The dependent variable is
normally distributed and the multiple linear regression
analysis did not obviously break the standard assumptions
of linear regression analysis. The values of the VIF
(Variance Inflation Factor) are generally below 2 and always
below 4, so there is no indication of high multicollinearity
[44]. The results found that presence of acute medical con-
ditions significantly influence the difference of the EQ-5D
and SF-6D; however, the magnitude of the influence was
not large (coefficient 0.043, P= 0.008). Similar results wereHyperlipidemia (vs. none) −0.011 (−0.038, 0.017) 0.439
Years with CAD 0.001 (−0.001, 0.002) 0.471
Patient sources (vs. Home)
Inpatients 0.072 (0.032, 0.113)*** 0.001
Outpatients 0.042 (0.009, 0.075)** 0.014
SAQ
Physical limitation 0.0007 (−0.0002, 0.002) 0.158
Angina stability 0.0003 (−0.0001, 0.0008) 0.129
Angina frequency 0.00001 (−0.0005, 0.001) 0.964
Treatment satisfaction −0.0003 (−0.001, 0.001) 0.516
Disease perception 0.0003 (−0.001, 0.001) 0.518
EQ-VAS 0.001 (0.00005, 0.002)* 0.040
R2 0.119 0.001
#SF-6D is the subtrahend; CI: confidence interval.
*P< 0.05; **P< 0.01; ***P< 0.001.
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A large magnitude of the influence was observed for
inpatient variable (coefficient 0.072, P= 0.001). A very
small magnitude of the influence was observed for
the EQ-VAS variable (coefficient 0.001, P= 0.040).
Discussion
The evidence of validity and sensitivity of the EQ-5D
and SF-6D in Chinese patients with stable angina was
provided in this study, which demonstrates that the
EQ-5D and SF-6D are valid and sensitive preference-based
HRQoL instruments in this patient group. However, the
performance of the two instruments was not identical.
Our results provide useful information for the choice of
preference-based HRQoL instruments for stable angina
patients. To our knowledge, this is the first comparison
study for the EQ-5D and SF-6D among stable angina
patients.
In this study, patients from Tianjin and Chengdu were
selected as our study sample. Previous evidence has
suggested that patient location does not affect the
validity of the results [13]. Therefore, samples from
the two cities were merged to increase the statistical
power and representativeness of study results. Convergent
validity was demonstrated by the moderate to strong
correlation coefficients with SAQ, a validated instrument
for angina, in our study. The correlations between
the utilities of the two instruments and two domains
of SAQ, physical limitation and disease perception,
were relatively strong. This is consistent with the
finding that illness perception is correlated with
poorer quality of life for cardiac patients [45]. As for
‘known group’ discriminative validity, both the EQ-
5D and SF-6D utility scores decreased with poorer
health status indicated by the EQ-VAS. Moreover,
both measures showed that female patients have lower
utility scores than male patients, as previously noted
[46]. Furthermore, the results also indicate that in-
creased utility scores are associated with higher educa-
tion level, but statistical significance is only achieved
in the SF-6D. This is consistent with previous studies
indicating that lower socioeconomic status is correlated
with poorer outcomes in patients with chronic diseases,
including cardiac patients [47,48].
Consistent with previous studies, ceiling effects existed
in the EQ-5D [13,20,49]. A total of 64 individuals (15.57%)
reported no limitations on all the EQ-5D dimensions,
while no patients were classified in full health on the
SF-6D. Based on the SF-6D responses, individuals reporting
full health on the EQ-5D may still have problems on
physical function, vitality and mental health dimensions.
This disparity can be attributed to the descriptive system
of the SF-6D, in which more response levels for each
domain are provided and patients might be morelikely to find the best description for their status. In
fact, a five-level version of the EQ-5D is under develop-
ment [50]. Preliminary studies indicated that prototype
five-level versions could improve the properties of the
three-level in terms of reduced ceiling effects, increased
reliability, and improved ability to discriminate between
different levels of health [51]. In addition, most of
the patients had better cardiac functioning indicated
by high SAQ scores, which can also partially explain
the strong ceiling effect. Effect sizes (ES), relative
efficiency (RE) statistics and AUC scores were used
to test the discriminative capacity of the EQ-5D and
SF-6D. Both instruments were able to detect the dif-
ferences between patients with different disease se-
verity as measured by the SAQ. It is shown that the
SF-6D had greater discriminatory power to detect
clinically relevant difference of stable angina patients.
This may be partially explained by the serious ceiling
effect of the EQ-5D. Previous studies showed that the
EQ-5D would be more suitable for measuring the health
of more morbidity while the SF-6D may have a limita-
tion in severe patients [18,49].
The mean EQ-5D score exceeded the mean SF-6D
score by 0.106 with significant difference, exceeding
minimally important differences (MIDs) of both measures
[18]. The magnitude of difference is higher than the
differences reported in other disease groups or general
population [18,20]. Interestingly, previous comparative
studies have estimated that the mean EQ-5D score was
higher than the SF-6D when the mean EQ-5D score
exceeded 0.740, which was consistent with our results
[15,52,53]. Conversely, mean EQ-5D utility was less than
mean SF-6D utility when the mean EQ-5D score was less
than 0.740 [19,54]. The ICC analyses and Bland-Altman
plot revealed the inconsistency of these instruments.
There were other differences between the two instruments
which may explain the different performance. The recall
period of both instruments is different is that ‘today’ for
the EQ-5D/VAS versus ‘the last four weeks’ for the SF-6D.
Another difference is the descriptive systems and the
valuations attached to the health states. The SF-6D
includes broader aspects of HRQoL and has more re-
sponse level for each domain. In the EQ-5D, health
status is valued using the time trade-off (TTO)
method, whereas the SF-6D assigns value to health
states using the standard gamble (SG) [55]. Also, in
the specific China scoring algorithm of the EQ-5D, if
any dimension is at level 3, a N3 term will be in-
cluded. The existence of N3 term in the China scoring
algorithm could be one of the reasons for the discrepancy
between EQ-5D and SF-6D. According to our results, the
SF-6D is shown to be more appropriate choice among
stable angina patients because of its higher sensitivity and
lower ceiling effect.
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cross-section study, we did not examine the longitudinal
response and reliability of the EQ-5D and SF-6D, for which
are important psychometric characteristics of instruments.
Secondly, the relatively small sample size of severe stable
angina patients might aggregate the ceiling effect. Further
studies with a larger sample size are warranted. Third,
similar to some previous studies, there were no objective
groups in our known-group analysis. All comparisons are
relative because there was no ‘gold standard’ objective
measure to compare the measures with.
Conclusions
The EQ-5D and SF-6D are demonstrated to be valid and
sensitive preference-based HRQoL instruments in Chinese
stable angina patients. The SF-6D may be a superior to
the EQ-5D, with a lower ceiling effect and greater sensitiv-
ity. Further study is needed to compare other properties,
such as reliability and longitudinal response.
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